{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:19:05Z","timestamp":1792718345740,"version":"4.5.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,8,5]],"date-time":"2017-08-05T00:00:00Z","timestamp":1501891200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s11894-017-0586-5","type":"journal-article","created":{"date-parts":[[2017,8,5]],"date-time":"2017-08-05T03:21:30Z","timestamp":1501903290000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe"],"prefix":"10.1007","volume":"19","author":[{"given":"C. Prakash","family":"Gyawali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,5]]},"reference":[{"key":"586_CR1","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0016-5085(00)70004-7","volume":"118","author":"MM Wolfe","year":"2000","unstructured":"Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology. 2000;118:S9\u201331.","journal-title":"Gastroenterology"},{"key":"586_CR2","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.cgh.2006.09.013","volume":"4","author":"IM Gralnek","year":"2006","unstructured":"Gralnek IM, Dulai GS, Fennerty MB, et al. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006;4:1452\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"586_CR3","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1001\/archinte.159.18.2161","volume":"159","author":"R Fass","year":"1999","unstructured":"Fass R, Ofman JJ, Gralnek IM, et al. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med. 1999;159:2161\u20138.","journal-title":"Arch Intern Med"},{"key":"586_CR4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1046\/j.1365-2036.2000.00733.x","volume":"14","author":"R Fass","year":"2000","unstructured":"Fass R, Ofman JJ, Sampliner RE, et al. The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. Aliment Pharmacol Ther. 2000;14:389\u201396.","journal-title":"Aliment Pharmacol Ther"},{"key":"586_CR5","doi-asserted-by":"crossref","first-page":"518","DOI":"10.7326\/0003-4819-140-7-200404060-00011","volume":"140","author":"ME Numans","year":"2004","unstructured":"Numans ME, Lau J, de Wit NJ, et al. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med. 2004;140:518\u201327.","journal-title":"Ann Intern Med"},{"key":"586_CR6","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/ajg.2013.421","volume":"109","author":"I Sheikh","year":"2014","unstructured":"Sheikh I, Waghray A, Waghray N, et al. Consumer use of over-the-counter proton pump inhibitors in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2014;109:789\u201394.","journal-title":"Am J Gastroenterol"},{"key":"586_CR7","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/ajg.2016.166","volume":"111","author":"A Lanas","year":"2016","unstructured":"Lanas A. We are using too many PPIs, and we need to stop: a European perspective. Am J Gastroenterol. 2016;111:1085\u20136.","journal-title":"Am J Gastroenterol"},{"key":"586_CR8","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","volume":"152","author":"DE Freedberg","year":"2017","unstructured":"\u2022\u2022 Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152:706\u201315. An excellent description of evidence and expert opinion-based best practice recommendations for appropriate long-term use of proton pump inhibitors.","journal-title":"Gastroenterology"},{"key":"586_CR9","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1053\/j.gastro.2008.08.045","volume":"135","author":"PJ Kahrilas","year":"2008","unstructured":"Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135:1383\u20131391, 1391 e1-5.","journal-title":"Gastroenterology"},{"key":"586_CR10","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1053\/gast.2001.24840","volume":"120","author":"MF Vela","year":"2001","unstructured":"Vela MF, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology. 2001;120:1599\u2013606.","journal-title":"Gastroenterology"},{"key":"586_CR11","doi-asserted-by":"crossref","first-page":"808","DOI":"10.7326\/0003-4819-157-11-201212040-00008","volume":"157","author":"NJ Shaheen","year":"2012","unstructured":"\u2022 Shaheen NJ, Weinberg DS, Denberg TD, et al. Upper endoscopy for gastroesophageal reflux disease: best practice advice from the clinical guidelines committee of the American College of Physicians. Ann Intern Med. 2012;157:808\u201316. Clinical guidelines for appropriate use of upper endoscopy in gastroesophageal reflux disease.","journal-title":"Ann Intern Med"},{"key":"586_CR12","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ajg.2012.444","volume":"108","author":"PO Katz","year":"2013","unstructured":"\u2022 Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308\u201328; quiz 329. Detailed description of indications for diagnostic testing, description of esophageal physiologic tests, and use of diagnostic testing in making management recommendations.","journal-title":"Am J Gastroenterol"},{"key":"586_CR13","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Sigterman KE, van Pinxteren B, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013; CD002095. Evidence on the value of short term use of acid suppression and prokinetic therapy in symptomatic foregut syndromes.","DOI":"10.1002\/14651858.CD002095.pub5"},{"key":"586_CR14","unstructured":"Khan M, Santana J, Donnellan C, et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev. 2007; CD003244."},{"key":"586_CR15","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2982.2012.01888.x","volume":"24","author":"PW Weijenborg","year":"2012","unstructured":"\u2022\u2022 Weijenborg PW, Cremonini F, Smout AJ, et al. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil. 2012;24:747\u201357, e350. Meta-analysis detailing the clinical value of proton pump inhibitors in erosive and well characterized nonerosive reflux disease.","journal-title":"Neurogastroenterol Motil"},{"key":"586_CR16","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1053\/j.gastro.2016.02.012","volume":"150","author":"Q Aziz","year":"2016","unstructured":"\u2022\u2022 Aziz Q, Fass R, Gyawali CP, et al. Functional esophageal disorders. Gastroenterology. 2016;150:1368\u201379. Current ROME IV diagnostic criteria for functional esophageal disorders and the basis for these criteria.","journal-title":"Gastroenterology"},{"key":"586_CR17","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/nmo.12864","volume":"28","author":"PW Weijenborg","year":"2016","unstructured":"Weijenborg PW, Smout AJ, Bredenoord AJ. Esophageal acid sensitivity and mucosal integrity in patients with functional heartburn. Neurogastroenterol Motil. 2016;28:1649\u201354.","journal-title":"Neurogastroenterol Motil"},{"key":"586_CR18","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/j.1365-2982.2010.01536.x","volume":"22","author":"E Savarino","year":"2010","unstructured":"Savarino E, Zentilin P, Frazzoni M, et al. Characteristics of gastro-esophageal reflux episodes in Barrett\u2019s esophagus, erosive esophagitis and healthy volunteers. Neurogastroenterol Motil. 2010;22:1061\u2013e280.","journal-title":"Neurogastroenterol Motil"},{"key":"586_CR19","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Roman S, Gyawali CP, Savarino E, et al. Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: Update of the Porto consensus and recommendations from an international consensus group. Neurogastroenterol Motil. 2017; Evidence and expert opinion on appropriate utilization of ambulatory reflux monitoring in GERD","DOI":"10.1111\/nmo.13067"},{"key":"586_CR20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12916-016-0718-z","volume":"14","author":"C Scarpignato","year":"2016","unstructured":"\u2022\u2022 Scarpignato C, Gatta L, Zullo A, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases\u2014A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14:179. A valuable resource detailing state-of-the-art evidence for appropriate use of proton pump inhibitors.","journal-title":"BMC Med"},{"key":"586_CR21","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.cgh.2012.01.022","volume":"10","author":"PJ Kahrilas","year":"2012","unstructured":"Kahrilas PJ, Jonsson A, Denison H, et al. Regurgitation is less responsive to acid suppression than heartburn in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2012;10:612\u20139.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"586_CR22","doi-asserted-by":"crossref","unstructured":"Chang AB, Lasserson TJ, Gaffney J, et al. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev. 2011; CD004823.","DOI":"10.1002\/14651858.CD004823.pub4"},{"key":"586_CR23","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1136\/gut.2011.241307","volume":"60","author":"PJ Kahrilas","year":"2011","unstructured":"Kahrilas PJ, Hughes N, Howden CW. Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. Gut. 2011;60:1473\u20138.","journal-title":"Gut"},{"key":"586_CR24","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/01.mlg.0000192173.00498.ba","volume":"116","author":"MF Vaezi","year":"2006","unstructured":"Vaezi MF, Richter JE, Stasney CR, et al. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope. 2006;116:254\u201360.","journal-title":"Laryngoscope"},{"key":"586_CR25","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/ajg.2011.146","volume":"106","author":"PJ Kahrilas","year":"2011","unstructured":"Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol. 2011;106:1419\u201325; quiz 1426.","journal-title":"Am J Gastroenterol"},{"key":"586_CR26","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/MCG.0b013e3181b8e97b","volume":"44","author":"MJ Hersh","year":"2010","unstructured":"Hersh MJ, Sayuk GS, Gyawali CP. Long-term therapeutic outcome of patients undergoing ambulatory pH monitoring for chronic unexplained cough. J Clin Gastroenterol. 2010;44:254\u201360.","journal-title":"J Clin Gastroenterol"},{"key":"586_CR27","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1164\/rccm.200507-1167OC","volume":"173","author":"TO Kiljander","year":"2006","unstructured":"Kiljander TO, Harding SM, Field SK, et al. Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2006;173:1091\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"586_CR28","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/j.1572-0241.2005.41657.x","volume":"100","author":"F Cremonini","year":"2005","unstructured":"Cremonini F, Wise J, Moayyedi P, et al. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol. 2005;100:1226\u201332.","journal-title":"Am J Gastroenterol"},{"key":"586_CR29","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1001\/archinte.165.11.1222","volume":"165","author":"WH Wang","year":"2005","unstructured":"Wang WH, Huang JQ, Zheng GF, et al. Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain?: a meta-analysis. Arch Intern Med. 2005;165:1222\u20138.","journal-title":"Arch Intern Med"},{"key":"586_CR30","first-page":"CD011969","volume":"3","author":"TA Boghossian","year":"2017","unstructured":"\u2022 Boghossian TA, Rashid FJ, Thompson W, et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst Rev. 2017;3:CD011969. Evidence for and against on demand use of acid suppression.","journal-title":"Cochrane Database Syst Rev"},{"key":"586_CR31","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ajg.2009.556","volume":"105","author":"KV Vasiliadis","year":"2010","unstructured":"Vasiliadis KV, Viazis N, Vlachogiannakos J, et al. Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless bravo pH system. Am J Gastroenterol. 2010;105:308\u201313.","journal-title":"Am J Gastroenterol"},{"key":"586_CR32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1572-0241.2001.03443.x","volume":"96","author":"DA Johnson","year":"2001","unstructured":"Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol. 2001;96:27\u201334.","journal-title":"Am J Gastroenterol"},{"key":"586_CR33","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1053\/gast.2001.28649","volume":"121","author":"JM Inadomi","year":"2001","unstructured":"Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology. 2001;121:1095\u2013100.","journal-title":"Gastroenterology"},{"key":"586_CR34","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jamcollsurg.2013.05.023","volume":"217","author":"BA Jobe","year":"2013","unstructured":"\u2022 Jobe BA, Richter JE, Hoppo T, et al. Preoperative diagnostic workup before antireflux surgery: an evidence and experience-based consensus of the esophageal diagnostic advisory panel. J Am Coll Surg. 2013;217:586\u201397. Expert opinion on preoperative diagnostic work up prior to antireflux surgery for GERD.","journal-title":"J Am Coll Surg"},{"key":"586_CR35","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1442-2050.2012.01384.x","volume":"26","author":"JE Richter","year":"2013","unstructured":"Richter JE, Pandolfino JE, Vela MF, et al. Utilization of wireless pH monitoring technologies: a summary of the proceedings from the esophageal diagnostic working group. Dis Esophagus. 2013;26:755\u201365.","journal-title":"Dis Esophagus"},{"key":"586_CR36","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/nmo.12620","volume":"27","author":"TV Herregods","year":"2015","unstructured":"Herregods TV, Troelstra M, Weijenborg PW, et al. Patients with refractory reflux symptoms often do not have GERD. Neurogastroenterol Motil. 2015;27:1267\u201373.","journal-title":"Neurogastroenterol Motil"},{"key":"586_CR37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1442-2050.2011.01322.x","volume":"26","author":"T Hershcovici","year":"2013","unstructured":"\u2022 Hershcovici T, Fass R. Step-by-step management of refractory gastresophageal reflux disease. Dis Esophagus. 2013;26:27\u201336. An approach to evaluation and management of refractory symptoms in GERD.","journal-title":"Dis Esophagus"},{"key":"586_CR38","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.gie.2009.08.024","volume":"71","author":"CH Poh","year":"2010","unstructured":"Poh CH, Gasiorowska A, Navarro-Rodriguez T, et al. Upper GI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment. Gastrointest Endosc. 2010;71:28\u201334.","journal-title":"Gastrointest Endosc"},{"key":"586_CR39","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/ajg.2013.71","volume":"108","author":"ES Dellon","year":"2013","unstructured":"\u2022 Dellon ES, Gonsalves N, Hirano I, et al. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol. 2013;108:679\u201392; quiz 693. Evidence based description of the use of proton pump inhibitors in the diagnosis and management of eosinophilic esophagitis.","journal-title":"Am J Gastroenterol"},{"key":"586_CR40","doi-asserted-by":"crossref","unstructured":"\u2022 Gyawali CP, Roman S, Bredenoord AJ, et al. Classification of esophageal motor findings in gastro-esophageal reflux disease: Conclusions from an international consensus group. Neurogastroenterol Motil. 2017; Characterization of findings on esophageal high resolution manometry in GERD","DOI":"10.1111\/nmo.13104"},{"key":"586_CR41","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1046\/j.1365-2036.2001.01109.x","volume":"15","author":"A Leodolter","year":"2001","unstructured":"Leodolter A, Kulig M, Brasch H, et al. A meta-analysis comparing eradication, healing and relapse rates in patients with helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther. 2001;15:1949\u201358.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"586_CR42","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1136\/gut.43.2008.S56","volume":"43","author":"D Scott","year":"1998","unstructured":"Scott D, Weeks D, Melchers K, et al. The life and death of Helicobacter pylori. Gut. 1998;43(Suppl 1):S56\u201360.","journal-title":"Gut"},{"key":"586_CR43","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1001\/jama.2017.1949","volume":"317","author":"RT Kavitt","year":"2017","unstructured":"Kavitt RT, Cifu AS. Management of Helicobacter pylori infection. JAMA. 2017;317:1572\u20133.","journal-title":"JAMA"},{"key":"586_CR44","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/07853890902887295","volume":"41","author":"RH Hunt","year":"2009","unstructured":"Hunt RH, Lanas A, Stichtenoth DO, et al. Myths and facts in the use of anti-inflammatory drugs. Ann Med. 2009;41:423\u201337.","journal-title":"Ann Med"},{"key":"586_CR45","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/MOG.0b013e328365efb1","volume":"29","author":"T Ito","year":"2013","unstructured":"Ito T, Igarashi H, Jensen RT. Zollinger-Ellison syndrome: recent advances and controversies. Curr Opin Gastroenterol. 2013;29:650\u201361.","journal-title":"Curr Opin Gastroenterol"},{"key":"586_CR46","doi-asserted-by":"crossref","first-page":"a1","DOI":"10.1055\/s-0034-1393172","volume":"47","author":"IM Gralnek","year":"2015","unstructured":"Gralnek IM, Dumonceau JM, Kuipers EJ, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2015;47:a1\u201346.","journal-title":"Endoscopy"},{"key":"586_CR47","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ajg.2011.480","volume":"107","author":"L Laine","year":"2012","unstructured":"\u2022 Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol. 2012;107:345\u201360; quiz 361. Current management of peptic ulcer bleeding.","journal-title":"Am J Gastroenterol"},{"key":"586_CR48","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cgh.2015.07.041","volume":"14","author":"AJ Lucendo","year":"2016","unstructured":"\u2022 Lucendo AJ, Arias A, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14:13\u201322 e1. Evidence for PPI use in eosinophilic esophagitis.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"586_CR49","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.amjmed.2016.04.024","volume":"129","author":"RT Kavitt","year":"2016","unstructured":"Kavitt RT, Hirano I, Vaezi MF. Diagnosis and treatment of eosinophilic esophagitis in adults. Am J Med. 2016;129:924\u201334.","journal-title":"Am J Med"},{"key":"586_CR50","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nrgastro.2014.235","volume":"12","author":"M Bardou","year":"2015","unstructured":"Bardou M, Quenot JP, Barkun A. Stress-related mucosal disease in the critically ill patient. Nat Rev Gastroenterol Hepatol. 2015;12:98\u2013107.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"586_CR51","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/CCM.0b013e3182758734","volume":"41","author":"W Alhazzani","year":"2013","unstructured":"Alhazzani W, Alenezi F, Jaeschke RZ, et al. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med. 2013;41:693\u2013705.","journal-title":"Crit Care Med"},{"key":"586_CR52","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1111\/j.1572-0241.2006.00847.x","volume":"101","author":"TB Gardner","year":"2006","unstructured":"Gardner TB, Robertson DJ. Stress ulcer prophylaxis in non-critically ill patients: less may be more. Am J Gastroenterol. 2006;101:2206\u20138.","journal-title":"Am J Gastroenterol"},{"key":"586_CR53","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13054-016-1305-6","volume":"20","author":"F Alshamsi","year":"2016","unstructured":"Alshamsi F, Belley-Cote E, Cook D, et al. Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care. 2016;20:120.","journal-title":"Crit Care"},{"key":"586_CR54","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2147\/TCRM.S81759","volume":"11","author":"S Shin","year":"2015","unstructured":"Shin S. Evaluation of costs accrued through inadvertent continuation of hospital-initiated proton pump inhibitor therapy for stress ulcer prophylaxis beyond hospital discharge: a retrospective chart review. Ther Clin Risk Manag. 2015;11:649\u201357.","journal-title":"Ther Clin Risk Manag"},{"key":"586_CR55","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/gut.2009.200063","volume":"59","author":"J Dent","year":"2010","unstructured":"Dent J, Vakil N, Jones R, et al. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond tudy. Gut. 2010;59:714\u201321.","journal-title":"Gut"},{"key":"586_CR56","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1056\/NEJMra1501505","volume":"373","author":"NJ Talley","year":"2015","unstructured":"\u2022\u2022 Talley NJ, Ford AC. Functional dyspepsia. N Engl J Med. 2015;373:1853\u201363. Modern evaluation and management of functional dyspepsia.","journal-title":"N Engl J Med"},{"key":"586_CR57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2036.2012.05128.x","volume":"36","author":"BE Lacy","year":"2012","unstructured":"Lacy BE, Talley NJ, Locke GR 3rd, et al. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther. 2012;36:3\u201315.","journal-title":"Aliment Pharmacol Ther"},{"key":"586_CR58","doi-asserted-by":"crossref","unstructured":"Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006; CD001960.","DOI":"10.1002\/14651858.CD001960.pub3"},{"key":"586_CR59","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1053\/j.gastro.2004.08.026","volume":"127","author":"P Moayyedi","year":"2004","unstructured":"Moayyedi P, Delaney BC, Vakil N, et al. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology. 2004;127:1329\u201337.","journal-title":"Gastroenterology"},{"key":"586_CR60","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Vaezi MF, Yang YX, Howden CW. Complications of Proton Pump Inhibitor Therapy. Gastroenterol. 2017; Detailed discussion of how to evaluate published literature addressing risks of long-term PPI therapy","DOI":"10.1053\/j.gastro.2017.04.047"},{"key":"586_CR61","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrgastro.2016.44","volume":"13","author":"L Kia","year":"2016","unstructured":"\u2022 Kia L, Kahrilas PJ. Therapy: risks associated with chronic PPI use - signal or noise? Nat Rev Gastroenterol Hepatol. 2016;13:253\u20134. Expert analysis of risks of proton pump inhibitor use.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"586_CR62","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12916-017-0804-x","volume":"15","author":"R Yadlapati","year":"2017","unstructured":"Yadlapati R, Kahrilas PJ. When is proton pump inhibitor use appropriate? BMC Med. 2017;15:36.","journal-title":"BMC Med"},{"key":"586_CR63","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.cgh.2012.11.031","volume":"11","author":"DA Johnson","year":"2013","unstructured":"Johnson DA, Oldfield ECT. Reported side effects and complications of long-term proton pump inhibitor use: dissecting the evidence. Clin Gastroenterol Hepatol. 2013;11:458\u201364; quiz e37-8.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"586_CR64","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2036.2007.03407.x","volume":"26","author":"F Sierra","year":"2007","unstructured":"Sierra F, Suarez M, Rey M, et al. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007;26:545\u201353.","journal-title":"Aliment Pharmacol Ther"},{"key":"586_CR65","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/ki.2014.74","volume":"86","author":"ML Blank","year":"2014","unstructured":"Blank ML, Parkin L, Paul C, et al. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014;86:837\u201344.","journal-title":"Kidney Int"},{"key":"586_CR66","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","volume":"176","author":"B Lazarus","year":"2016","unstructured":"Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176:238\u201346.","journal-title":"JAMA Intern Med"},{"key":"586_CR67","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s40620-016-0309-2","volume":"29","author":"DG Moledina","year":"2016","unstructured":"Moledina DG, Perazella MA. PPIs and kidney disease: from AIN to CKD. J Nephrol. 2016;29:611\u20136.","journal-title":"J Nephrol"},{"key":"586_CR68","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2369-14-150","volume":"14","author":"DG Klepser","year":"2013","unstructured":"Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case-control study. BMC Nephrol. 2013;14:150.","journal-title":"BMC Nephrol"},{"key":"586_CR69","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMc066308","volume":"355","author":"M Epstein","year":"2006","unstructured":"Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355:1834\u20136.","journal-title":"N Engl J Med"},{"key":"586_CR70","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3109\/0886022X.2015.1057800","volume":"37","author":"W Cheungpasitporn","year":"2015","unstructured":"Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail. 2015;37:1237\u201341.","journal-title":"Ren Fail"},{"key":"586_CR71","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cgh.2015.10.012","volume":"14","author":"AI Sharara","year":"2016","unstructured":"Sharara AI, Chalhoub JM, Hammoud N, et al. Low prevalence of hypomagnesemia in long-term recipients of proton pump inhibitors in a managed care cohort. Clin Gastroenterol Hepatol. 2016;14:317\u201321.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"586_CR72","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/ajg.2015.119","volume":"110","author":"GM Masclee","year":"2015","unstructured":"Masclee GM, Coloma PM, Kuipers EJ, et al. Increased risk of microscopic colitis with use of proton pump inhibitors and non-steroidal anti-inflammatory drugs. Am J Gastroenterol. 2015;110:749\u201359.","journal-title":"Am J Gastroenterol"},{"key":"586_CR73","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.dld.2010.11.015","volume":"43","author":"G Capurso","year":"2011","unstructured":"Capurso G, Marignani M, Attilia F, et al. Lansoprazole-induced microscopic colitis: an increasing problem? Results of a prospecive case-series and systematic review of the literature. Dig Liver Dis. 2011;43:380\u20135.","journal-title":"Dig Liver Dis"},{"key":"586_CR74","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1017\/ice.2014.39","volume":"36","author":"L Furuya-Kanamori","year":"2015","unstructured":"Furuya-Kanamori L, Stone JC, Clark J, et al. Comorbidities, exposure to medications, and the risk of community-acquired Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015;36:132\u201341.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"586_CR75","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/ajg.2015.22","volume":"110","author":"IM Zacharioudakis","year":"2015","unstructured":"Zacharioudakis IM, Zervou FN, Pliakos EE, et al. Colonization with toxinogenic C. difficile upon hospital admission, and risk of infection: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110:381\u201390; quiz 391.","journal-title":"Am J Gastroenterol"},{"key":"586_CR76","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1503\/cmaj.1040876","volume":"171","author":"S Dial","year":"2004","unstructured":"Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 2004;171:33\u20138.","journal-title":"CMAJ"},{"key":"586_CR77","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/j.1365-2036.2011.04874.x","volume":"34","author":"C Bavishi","year":"2011","unstructured":"Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011;34:1269\u201381.","journal-title":"Aliment Pharmacol Ther"},{"key":"586_CR78","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/j.1572-0241.2007.01275.x","volume":"102","author":"J Leonard","year":"2007","unstructured":"Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102:2047\u201356; quiz 2057.","journal-title":"Am J Gastroenterol"},{"key":"586_CR79","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cgh.2012.12.011","volume":"11","author":"WK Lo","year":"2013","unstructured":"Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11:483\u201390.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"586_CR80","doi-asserted-by":"crossref","first-page":"7490","DOI":"10.4238\/2015.July.3.25","volume":"14","author":"HB Xu","year":"2015","unstructured":"Xu HB, Wang HD, Li CH, et al. Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis. Genet Mol Res. 2015;14:7490\u2013501.","journal-title":"Genet Mol Res"},{"key":"586_CR81","doi-asserted-by":"crossref","first-page":"391","DOI":"10.7326\/0003-4819-149-6-200809160-00005","volume":"149","author":"M Sarkar","year":"2008","unstructured":"Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149:391\u20138.","journal-title":"Ann Intern Med"},{"key":"586_CR82","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/apt.13304","volume":"42","author":"L Estborn","year":"2015","unstructured":"Estborn L, Joelson S. Frequency and time to onset of community-acquired respiratory tract infections in patients receiving esomeprazole: a retrospective analysis of patient-level data in placebo-controlled studies. Aliment Pharmacol Ther. 2015;42:607\u201313.","journal-title":"Aliment Pharmacol Ther"},{"key":"586_CR83","doi-asserted-by":"crossref","first-page":"e0128004","DOI":"10.1371\/journal.pone.0128004","volume":"10","author":"AA Lambert","year":"2015","unstructured":"Lambert AA, Lam JO, Paik JJ, et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10:e0128004.","journal-title":"PLoS One"},{"key":"586_CR84","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11894-010-0141-0","volume":"12","author":"T Ito","year":"2010","unstructured":"Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 2010;12:448\u201357.","journal-title":"Curr Gastroenterol Rep"},{"key":"586_CR85","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.gastro.2016.11.023","volume":"152","author":"JR Lam","year":"2017","unstructured":"Lam JR, Schneider JL, Quesenberry CP, et al. Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency. Gastroenterology. 2017;152:821\u2013829 e1.","journal-title":"Gastroenterology"},{"key":"586_CR86","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1001\/jama.2013.280490","volume":"310","author":"JR Lam","year":"2013","unstructured":"Lam JR, Schneider JL, Zhao W, et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310:2435\u201342.","journal-title":"JAMA"},{"key":"586_CR87","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/ajg.2011.113","volume":"106","author":"S Ngamruengphong","year":"2011","unstructured":"Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106:1209\u201318; quiz 1219.","journal-title":"Am J Gastroenterol"},{"key":"586_CR88","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","volume":"296","author":"YX Yang","year":"2006","unstructured":"Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947\u201353.","journal-title":"JAMA"},{"key":"586_CR89","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamaneurol.2015.4791","volume":"73","author":"W Gomm","year":"2016","unstructured":"Gomm W, von Holt K, Thome F, et al. Association of Proton Pump Inhibitors With Risk of Dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73:410\u20136.","journal-title":"JAMA Neurol"},{"key":"586_CR90","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00406-014-0554-0","volume":"265","author":"B Haenisch","year":"2015","unstructured":"Haenisch B, von Holt K, Wiese B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci. 2015;265:419\u201328.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"586_CR91","doi-asserted-by":"crossref","unstructured":"Goldstein FC, Steenland K, Zhao L, et al. Proton pump inhibitors and risk of mild cognitive impairment and dementia. J Am Geriatr Soc. 2017;","DOI":"10.1111\/jgs.14956"},{"key":"586_CR92","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","volume":"363","author":"DL Bhatt","year":"2010","unstructured":"Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909\u201317.","journal-title":"N Engl J Med"},{"key":"586_CR93","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/j.1365-2036.2009.03993.x","volume":"29","author":"E Lahner","year":"2009","unstructured":"Lahner E, Annibale B, Delle FG. Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy. Aliment Pharmacol Ther. 2009;29:1219\u201329.","journal-title":"Aliment Pharmacol Ther"},{"key":"586_CR94","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1053\/hupa.2000.7637","volume":"31","author":"A Cats","year":"2000","unstructured":"Cats A, Schenk BE, Bloemena E, et al. Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol. 2000;31:684\u201390.","journal-title":"Hum Pathol"},{"key":"586_CR95","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/j.1365-2036.2006.03127.x","volume":"24","author":"M Jalving","year":"2006","unstructured":"Jalving M, Koornstra JJ, Wesseling J, et al. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther. 2006;24:1341\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"586_CR96","first-page":"CD010623","volume":"12","author":"H Song","year":"2014","unstructured":"Song H, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev. 2014;12:CD010623.","journal-title":"Cochrane Database Syst Rev"},{"key":"586_CR97","doi-asserted-by":"crossref","first-page":"e0124653","DOI":"10.1371\/journal.pone.0124653","volume":"10","author":"NH Shah","year":"2015","unstructured":"Shah NH, LePendu P, Bauer-Mehren A, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 2015;10:e0124653.","journal-title":"PLoS One"},{"key":"586_CR98","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/MCC.0b013e32832978e0","volume":"15","author":"JP Quenot","year":"2009","unstructured":"Quenot JP, Thiery N, Barbar S. When should stress ulcer prophylaxis be used in the ICU? Curr Opin Crit Care. 2009;15:139\u201343.","journal-title":"Curr Opin Crit Care"},{"key":"586_CR99","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/nmo.12221","volume":"26","author":"N Bortoli de","year":"2014","unstructured":"\u2022\u2022 de Bortoli N, Martinucci I, Savarino E, et al. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they? Neurogastroenterol Motil. 2014;26:28\u201335. Follow-up and phenotyping of responders and non-responders of short-term PPI therapy administered for heartburn with normal endoscopy.","journal-title":"Neurogastroenterol Motil"},{"key":"586_CR100","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/archinte.166.9.965","volume":"166","author":"T Kaltenbach","year":"2006","unstructured":"Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med. 2006;166:965\u201371.","journal-title":"Arch Intern Med"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11894-017-0586-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-017-0586-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-017-0586-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T22:12:23Z","timestamp":1569967943000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11894-017-0586-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,5]]},"references-count":100,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["586"],"URL":"https:\/\/doi.org\/10.1007\/s11894-017-0586-5","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,5]]},"article-number":"46"}}